现场格拉斯哥昏迷量表与GCS运动评分对亚洲创伤患者30天死亡率和功能结局预测的比较
本研究利用泛亚洲创伤结局研究注册数据库,纳入2016年1月1日至2018年11月30日期间经急救医疗服务到达医院的>18岁创伤患者,比较现场GCS与GCS-M预测30天死亡率和出院时严重残疾(MRS≥4)的准确性。30天死亡率为1.04%,GCS与GCS-M的AUROC分别为0.917(95%CI 0.887-0.946)与0.907(95%CI 0.875-0.938),P=0.155;不良功能结局发生率为12.4%,AUROC分别为0.617(95%CI 0.597-0.637)与0.613(95%CI 0.593-0.633),P=0.616。TBI与非TBI亚组分析结果一致。结论认为院前GCS-M与GCS预测能力相当。
要点
- 在16218例30天死亡率分析中,现场GCS与GCS-M的AUROC分别为0.917(95%CI 0.887-0.946)与0.907(95%CI 0.875-0.938),P=0.155,无显著差异。
- 在11653例功能结局分析中,GCS与GCS-M预测MRS≥4的AUROC分别为0.617(95%CI 0.597-0.637)与0.613(95%CI 0.593-0.633),P=0.616。
- TBI与非TBI亚组分析显示GCS与GCS-M区分能力一致:30天死亡率AUROC 0.92(0.821-1.0)vs 0.92(0.824-1.0),P=0.64;不良功能结局0.75(0.72-0.78)vs 0.74(0.717-0.758),P=0.21。
- 研究纳入>18岁、经急救医疗服务到达医院的创伤患者,来自泛亚洲创伤结局研究注册数据库,时间范围为2016年1月1日至2018年11月30日。
- 主要结局30天死亡率为1.04%,次要结局出院时MRS≥4的发生率为12.4%。
适用人群与场景
- 纳入标准:>18岁创伤患者,经急救医疗服务到达医院,来自泛亚洲创伤结局研究注册数据库,时间2016年1月1日至2018年11月30日。
- 30天死亡率分析共16218例,功能结局分析共11653例。
- 亚组分析包括创伤性脑损伤(TBI)患者和无TBI患者。
诊断标准与关键阈值
- 严重残疾定义为出院时改良Rankin量表(MRS)评分≥4。
研究设计与关键结果
- 研究类型:基于泛亚洲创伤结局研究注册数据库的多中心队列分析;样本量:30天死亡率分析16218例,功能结局分析11653例;人群:>18岁经急救医疗服务到达医院的创伤患者。
- 主要终点30天死亡率1.04%,GCS预测AUROC 0.917(95%CI 0.887-0.946)vs GCS-M 0.907(95%CI 0.875-0.938),P=0.155。
- 次要终点出院时MRS≥4发生率12.4%,GCS预测AUROC 0.617(95%CI 0.597-0.637)vs GCS-M 0.613(95%CI 0.593-0.633),P=0.616。
- TBI与非TBI亚组分析显示GCS与GCS-M区分能力一致:30天死亡率AUROC 0.92(0.821-1.0)vs 0.92(0.824-1.0),P=0.64;不良功能结局AUROC 0.75(0.72-0.78)vs 0.74(0.717-0.758),P=0.21。
证据类型、等级与局限
- 证据类型:基于注册数据库的多中心队列分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在院前环境中,现场GCS-M预测创伤患者30天死亡率和不良功能结局的能力与完整GCS相当,无论是否合并TBI。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND AND IMPORTANCE: This study compared the on-scene Glasgow Coma Scale (GCS) and the GCS-motor (GCS-M) for predictive accuracy of mortality and severe disability using a large, multicenter population of trauma patients in Asian countries.
OBJECTIVE: To compare the ability of the prehospital GCS and GCS-M to predict 30-day mortality and severe disability in trauma patients.
DESIGN: We used the Pan-Asia Trauma Outcomes Study registry to enroll all trauma patients >18 years of age who presented to hospitals via emergency medical services from 1 January 2016 to November 30, 2018.
SETTINGS AND PARTICIPANTS: A total of 16,218 patients were included in the analysis of 30-day mortality and 11 653 patients in the analysis of functional outcomes.
OUTCOME MEASURES AND ANALYSIS: The primary outcome was 30-day mortality after injury, and the secondary outcome was severe disability at discharge defined as a Modified Rankin Scale (MRS) score ≥4. Areas under the receiver operating characteristic curve (AUROCs) were compared between GCS and GCS-M for these outcomes. Patients with and without traumatic brain injury (TBI) were analyzed separately. The predictive discrimination ability of logistic regression models for outcomes (30-day mortality and MRS) between GCS and GCS-M is illustrated using AUROCs.
MAIN RESULTS: The primary outcome for 30-day mortality was 1.04% and the AUROCs and 95% confidence intervals for prediction were GCS: 0.917 (0.887-0.946) vs. GCS-M:0.907 (0.875-0.938), P = 0.155. The secondary outcome for poor functional outcome (MRS ≥ 4) was 12.4% and the AUROCs and 95% confidence intervals for prediction were GCS: 0.617 (0.597-0.637) vs. GCS-M: 0.613 (0.593-0.633), P = 0.616. The subgroup analyses of patients with and without TBI demonstrated consistent discrimination ability between the GCS and GCS-M. The AUROC values of the GCS vs. GCS-M models for 30-day mortality and poor functional outcome were 0.92 (0.821-1.0) vs. 0.92 (0.824-1.0) ( P = 0.64) and 0.75 (0.72-0.78) vs. 0.74 (0.717-0.758) ( P = 0.21), respectively.
CONCLUSION: In the prehospital setting, on-scene GCS-M was comparable to GCS in predicting 30-day mortality and poor functional outcomes among patients with trauma, whether or not there was a TBI.
参考来源
- Chien YC, Chiang WC, Chen CH, et al. Comparison of on-scene Glasgow Coma Scale with GCS-motor for prediction of 30-day mortality and functional outcomes of patients with trauma in Asia. Eur J Emerg Med. 2023. PMID: 38100651. doi:10.1097/MEJ.0000000000001110
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。